Market Overview

Benzinga's Top Pre-Market Losers

Share:
Related HALO
New Drug Could Transform Pancreatic Cancer Treatment
Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animals
Related ENTR
MaxLinear and Entropic Announce Early Termination of Hart-Scott-Rodino Waiting Period for MaxLinear's Pending Acquisition of Entropic
MaxLinear Gains On Merger Deal With Entropic Communications

Halozyme Therapeutics (NASDAQ: HALO) dipped 20.68% to $6.75 in the pre-market session after the company provided update on ViroPharma Phase 2 study of subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) with recombinant human hyaluronidase.

Entropic Communications (NASDAQ: ENTR) shares fell 16.48% to $3.70 in the pre-market trading after the company reported Q2 results. Benchmark downgraded Entropic from “buy” to “hold.”

Reliv International (NASDAQ: RELV) shares dropped 15.57% to $3.09 in pre-market trading after the company posted a Q2 net loss of $214,000, versus a year-ago net income of $103,000.

NII Holdings (NASDAQ: NIHD) dipped 6.94% to $6.70 in the pre-market session on second-quarter results.

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets

 

Related Articles (ENTR + HALO)

Around the Web, We're Loving...

Get Benzinga's Newsletters